Keating Susan M, Clark Kevin R, Stefanich Lisa D, Arellano Fred, Edwards Caroline P, Bodary Sarah C, Spencer Steven A, Gadek Thomas R, Marsters James C, Beresini Maureen H
Department of BioAnalytical Research and Development, Genentech, Inc., 1 DNA Way, South San Francisco, CA 94080, USA.
Protein Sci. 2006 Feb;15(2):290-303. doi: 10.1110/ps.051583406. Epub 2005 Dec 29.
The lymphocyte function-associated antigen-1 (LFA-1) binding of a unique class of small-molecule antagonists as represented by compound 3 was analyzed in comparison to that of soluble intercellular adhesion molecule-1 (sICAM-1) and A-286982, which respectively define direct and allosteric competitive binding sites within LFA-1's inserted (I) domain. All three molecules antagonized LFA-1 binding to ICAM-1-Immunoglobulin G fusion (ICAM-1-Ig) in a competition ELISA, but only compound 3 and sICAM-1 inhibited the binding of a fluorescein-labeled analog of compound 3 to LFA-1. Compound 3 and sICAM-1 displayed classical direct competitive binding behavior with ICAM-1. Their antagonism of LFA-1 was surmountable by both ICAM-1-Ig and a fluorescein-labeled compound 3 analog. The competition of both sICAM-1 and compound 3 with ICAM-1-Ig for LFA-1 resulted in equivalent and linear Schild plots with slopes of 1.24 and 1.26, respectively. Cross-linking studies with a photoactivated analog of compound 3 localized the high-affinity small-molecule binding site to the N-terminal 507 amino acid segment of the alpha chain of LFA-1, a region that includes the I domain. In addition, cells transfected with a variant of LFA-1 lacking this I domain showed no significant binding of a fluorescein-labeled analog of compound 3 or ICAM-1-Ig. These results demonstrate that compound 3 inhibits the LFA-1/ICAM-1 binding interaction in a directly competitive manner by binding to a high-affinity site on LFA-1. This binding site overlaps with the ICAM-1 binding site on the alpha subunit of LFA-1, which has previously been localized to the I domain.
以化合物3为代表的一类独特小分子拮抗剂与淋巴细胞功能相关抗原-1(LFA-1)的结合情况,与可溶性细胞间黏附分子-1(sICAM-1)和A-286982进行了比较分析,sICAM-1和A-286982分别定义了LFA-1插入(I)结构域内的直接和别构竞争结合位点。在竞争酶联免疫吸附测定(ELISA)中,这三种分子均拮抗LFA-1与细胞间黏附分子-1-免疫球蛋白G融合蛋白(ICAM-1-Ig)的结合,但只有化合物3和sICAM-1抑制了荧光素标记的化合物3类似物与LFA-1的结合。化合物3和sICAM-1与ICAM-1表现出典型的直接竞争结合行为。ICAM-1-Ig和荧光素标记的化合物3类似物均可克服它们对LFA-1的拮抗作用。sICAM-1和化合物3与ICAM-1-Ig竞争LFA-1的结果产生了等效且呈线性的Schild图,斜率分别为1.24和1.26。用化合物3的光活化类似物进行的交联研究将高亲和力小分子结合位点定位到LFA-1α链的N端507个氨基酸片段,该区域包括I结构域。此外,转染了缺乏该I结构域的LFA-1变体的细胞对荧光素标记的化合物3类似物或ICAM-1-Ig均无明显结合。这些结果表明,化合物3通过与LFA-1上的高亲和力位点结合,以直接竞争的方式抑制LFA-1/ICAM-1结合相互作用。该结合位点与LFA-1α亚基上的ICAM-1结合位点重叠,ICAM-1结合位点先前已定位到I结构域。